|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||349.27 - 354.76|
|52-week range||344.63 - 509.62|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
HERCULES, Calif., August 28, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Wells Fargo’s 2023 Healthcare Conference on Thursday, September 7 at 11:00 AM Eastern Time (8:00 AM Pacific Time).
HERCULES, Calif., August 03, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023.
HERCULES, Calif., & VENLO, the Netherlands, July 26, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.